Abstract
The Transforming Growth Factor (TGF)-β-Smad signaling pathway regulates diverse biological processes essential for normal development and homeostasis. The Smad-interacting transcriptional modulator SnoN and its related homologs have emerged as important modulators of TGF-β signaling and responses. SnoN forms a physical complex with the TGF-β-regulated Smad2/Smad3 and co-Smad4 proteins and either represses or stimulates TGF-β-induced Smad-dependent transcription in a cell- and promoter-specific manner. In addition, the TGF-β-activated Smads recruit several ubiquitin ligases to SnoN and thereby promote the ubiquitination and consequent degradation of SnoN. Additional modifications of SnoN, including sumoylation, may contribute to the regulation of SnoN function and its role in TGF-β signaling. Collectively, these studies suggest that SnoN function is intimately linked to the TGF-β-Smad pathway in cellular signaling. Although the mechanisms by which SnoN modulates signaling in the TGF-β-Smad pathway are beginning to be characterized, the full range of SnoN functions and underlying mechanisms in normal development and disease processes remains to be elucidated.
Keywords: SnoN, Ski, TGF-β, Smad, signaling, transcription control, cell cycle, cancer
Current Molecular Medicine
Title: SnoN in TGF-β Signaling and Cancer Biology
Volume: 8 Issue: 4
Author(s): Isabelle Pot and Shirin Bonni
Affiliation:
Keywords: SnoN, Ski, TGF-β, Smad, signaling, transcription control, cell cycle, cancer
Abstract: The Transforming Growth Factor (TGF)-β-Smad signaling pathway regulates diverse biological processes essential for normal development and homeostasis. The Smad-interacting transcriptional modulator SnoN and its related homologs have emerged as important modulators of TGF-β signaling and responses. SnoN forms a physical complex with the TGF-β-regulated Smad2/Smad3 and co-Smad4 proteins and either represses or stimulates TGF-β-induced Smad-dependent transcription in a cell- and promoter-specific manner. In addition, the TGF-β-activated Smads recruit several ubiquitin ligases to SnoN and thereby promote the ubiquitination and consequent degradation of SnoN. Additional modifications of SnoN, including sumoylation, may contribute to the regulation of SnoN function and its role in TGF-β signaling. Collectively, these studies suggest that SnoN function is intimately linked to the TGF-β-Smad pathway in cellular signaling. Although the mechanisms by which SnoN modulates signaling in the TGF-β-Smad pathway are beginning to be characterized, the full range of SnoN functions and underlying mechanisms in normal development and disease processes remains to be elucidated.
Export Options
About this article
Cite this article as:
Pot Isabelle and Bonni Shirin, SnoN in TGF-β Signaling and Cancer Biology, Current Molecular Medicine 2008; 8 (4) . https://dx.doi.org/10.2174/156652408784533797
DOI https://dx.doi.org/10.2174/156652408784533797 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Recent Clinical Advances in the Treatment of Cutaneous Melanoma
Clinical Cancer Drugs Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Analysis of DNA Microarray Data
Current Topics in Medicinal Chemistry BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Current Pharmaceutical Design Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
Medicinal Chemistry The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting the Spindle Assembly Checkpoint for Breast Cancer Treatment
Current Cancer Drug Targets Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology An EJC Factor RBM8a Regulates Anxiety Behaviors
Current Molecular Medicine Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets